…
"You really have to dig into individual companies and sectors," says the T. Rowe Price strategist, naming some of his…
…
…
Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs…
This competition is leading to a lot of serious innovation.…
Eli Lilly: still seeking UK approval on pen for weight-loss drug…
One of this year’s hottest stocks is on pace for its worst day of the year.
Eli Lilly shares are down…
…
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.…
Howie and Harlan are joined by the New Yorkers Dhruv Khullar to talk about his life as a clinician, researcher,…
Shares of Eli Lilly jumped Wednesday after the U.S. gave the green light for the companys blockbuster GLP-1 drug to…
Eli Lilly gets FDA approval for new obesity drug…
Zepbound helped patients lose up to 48 pounds on average in clinical trials.…
…
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug…
Aggressive investments in growth have left the pharma giant with smaller profits this year.…
Eli Lilly was a strong performer Monday, while energy plays were among the indexs biggest winners and losers.…
…
…
…
An der US-amerikanischen Börse liegt die Eli Lilly-Aktie derzeit im Plus. Das Papier kostete zuletzt 590,69 US-Dollar. Im US-amerikanischen Wertpapierhandel…
The answer is relatively clear.…
Lillys Mounjaro is gaining ground on Novo Nordisks Ozempic.…
Lillys Mounjaro is gaining ground on Novo Nordisks Ozempic.…
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro…
The case for owning Eli Lilly got stronger Thursday, as diabetes drug Mounjaro crossed $1 billion in quarterly sales for…
LLY earnings call for the period ending September 30, 2023.…
These are the stocks posting the largest moves in midday trading.…
The remarks suggest that Eli Lillys initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for…
Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug...…
INDIANAPOLIS (dpa-AFX) - Der Pharmakonzern Eli Lilly and Company wächst weiter rasant. Auch im vergangenen…
…
…
INDIANAPOLIS (dpa-AFX) - Der Pharmakonzern Lilly wächst weiter rasant. Auch im vergangenen Quartal konnte sich…
Here are Thursdays biggest calls on Wall Street.…
Eli Lilly reported revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes…
Eli Lillys Mounjaro, a diabetes drug that is expected to received FDA approval for weight loss treatment, generated more than…
Eli Lilly beats quarterly revenue estimates on Mounjaro strength…
Eli Lilly falls after cutting full-year profit forecast…
Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on…
Apple earnings, Eli Lilly, ConocoPhillips: 3 things to watch…
Eli Lilly now owns the opt-in rights to three more of Verves cardiovascular drugs.…
Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics…
…
…
The earnings season also continues with Apple, Airbnb, McDonalds, Moderna and Eli Lilly.…
Companies — both big and small — are hoping to grab a piece of the lucrative anti-obesity drug market. Piper…
Eli Lilly and Co (NYSE:LLY) is scheduled to report earnings before the market opens on Thursday, with analysts expecting revenue…
Eli Lilly and Co (NYSE:LLY) has announced that its Omvoh drug has been approved by the US Food and Drug…